Home > Resources > Whitepapers > The Strategic Importance of Biomarkers to the Pharmaceutical Industry

The Strategic Importance of Biomarkers to the Pharmaceutical Industry

In the last few years, pharmaceutical companies have become increasingly interested in biomarkers and their incorporation into company drug development programmes and use as companion tests for targeted therapeutics. Identifying patients that will benefit from a drug and eliminating those that will not is increasingly important. A simple analysis of the number of biomarker deals recorded in PharmaVentures' PharmaDeals database shows a rise from just seven in 2001 to 130 in 2007. There are a number of drivers for this, and these include: the increasing cost of drug development and associated decline in new molecular entities (NMEs) achieving registration; patient and regulatory authorities requesting upfront evidence of therapeutic benefit; and reimbursing bodies requiring proof of likely beneficial outcomes before payment. One would imagine that the combination of these factors would result in a highly positive outlook for biomarker researchers and developers. However, the situation is not as simple as it appears because, despite the factors listed above, it is hard to capture the value created by the addition of a biomarker into the drug development or patient identification process, and thus to apportion returns from subsequent commercialization of the drug and/or biomarker.

I'm For Real

Enter your details once to access all our information and resources

Spotlight

PHARMACOS

BECAUSE EACH OF YOUR DECISIONS MUST BE PERENNE. Engineering consulting firm, we develop sustainable solutions for the pharmaceutical and biotechnology industries. Our presence is strong on 3 levels: 1 / Design assistance on all phases of your projects 2 / Project management, qualification and validation of equipment and process 3 / Control of industrialization risks for boiler equipment and piping Our Customers They are as large groups in the pharmaceutical sector as they are medium-sized biotech companies.

OTHER WHITEPAPERS
news image

Choosing the Right Temperature Monitoring Solution

whitePaper | April 24, 2023

Globally, pharmaceutical regulators are becoming attuned to cold chain issues as biologics, vaccines, and other temperature‐sensitive products are commercialized for a global clientele. Many regulators now recommend including temperature monitoring technology in every cold chain shipment.

Read More
news image

Simulation in the pharmaceutical industry

whitePaper | November 24, 2022

The pharmaceutical industry will face many challenges over the next decade, from industry-wide trends to new operational pressures. The key to meeting these challenges is adopting an agile, scalable and efficient approach to drug discovery and manufacturing.

Read More
news image

Discovering Effective Strategies for Sales and Marketing in the Face of Reduced Access to Oncologists

whitePaper | January 15, 2023

Oncology breakthroughs are currently fueling significant growth in the market, as well as the competition between pharmaceutical brands for market share. As increasingly individualized cancer treatments become available,

Read More
news image

QbD and PAT in Biopharmaceutical Development

whitePaper | July 12, 2022

As the pharmaceutical industry tries to embrace the methodologies of quality by design (QbD) provided by the FDA ’s process validation (PV) guidance (1) and International Conference on Harmonization.

Read More
news image

WILL PHARMA COMMIT TO DELIVERING AFFORDABLE THERAPEUTICS AGAINST COVID-19?

whitePaper | April 8, 2020

EPHA is a change agent – Europe’s leading NGO alliance advocating for better health. We are a dynamic member-led organisation, made up of public health civil society, patient groups, health professionals, and disease groups working together to improve health and strengthen the voice of public health in Europe.

Read More
news image

Employing Singleuse Technology to Control Frozen Bulk Drug Storage

whitePaper | September 29, 2022

New biopharmaceutical drug products that alter and even save lives can be very profitable for their developers.

Read More

Choosing the Right Temperature Monitoring Solution

whitePaper | April 24, 2023

Globally, pharmaceutical regulators are becoming attuned to cold chain issues as biologics, vaccines, and other temperature‐sensitive products are commercialized for a global clientele. Many regulators now recommend including temperature monitoring technology in every cold chain shipment.

Read More

Simulation in the pharmaceutical industry

whitePaper | November 24, 2022

The pharmaceutical industry will face many challenges over the next decade, from industry-wide trends to new operational pressures. The key to meeting these challenges is adopting an agile, scalable and efficient approach to drug discovery and manufacturing.

Read More

Discovering Effective Strategies for Sales and Marketing in the Face of Reduced Access to Oncologists

whitePaper | January 15, 2023

Oncology breakthroughs are currently fueling significant growth in the market, as well as the competition between pharmaceutical brands for market share. As increasingly individualized cancer treatments become available,

Read More

QbD and PAT in Biopharmaceutical Development

whitePaper | July 12, 2022

As the pharmaceutical industry tries to embrace the methodologies of quality by design (QbD) provided by the FDA ’s process validation (PV) guidance (1) and International Conference on Harmonization.

Read More

WILL PHARMA COMMIT TO DELIVERING AFFORDABLE THERAPEUTICS AGAINST COVID-19?

whitePaper | April 8, 2020

EPHA is a change agent – Europe’s leading NGO alliance advocating for better health. We are a dynamic member-led organisation, made up of public health civil society, patient groups, health professionals, and disease groups working together to improve health and strengthen the voice of public health in Europe.

Read More

Employing Singleuse Technology to Control Frozen Bulk Drug Storage

whitePaper | September 29, 2022

New biopharmaceutical drug products that alter
and even save lives can be very profitable for their
developers.

Read More
More Whitepapers

Spotlight

PHARMACOS

BECAUSE EACH OF YOUR DECISIONS MUST BE PERENNE. Engineering consulting firm, we develop sustainable solutions for the pharmaceutical and biotechnology industries. Our presence is strong on 3 levels: 1 / Design assistance on all phases of your projects 2 / Project management, qualification and validation of equipment and process 3 / Control of industrialization risks for boiler equipment and piping Our Customers They are as large groups in the pharmaceutical sector as they are medium-sized biotech companies.

Events

National Medtech & Biotech Summit 2024

Conference